KTTA (Pasithea Therapeutics) Short-Term Capital Lease Obligation : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Pasithea Therapeutics Short-Term Capital Lease Obligation?

Pasithea Therapeutics's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.00 Mil.

Pasithea Therapeutics's annual Short-Term Capital Lease Obligation declined from Dec. 2022 ($0.16 Mil) to Dec. 2023 ($0.08 Mil) and declined from Dec. 2023 ($0.08 Mil) to Dec. 2024 ($0.00 Mil).

Pasithea Therapeutics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Pasithea Therapeutics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pasithea Therapeutics Short-Term Capital Lease Obligation Chart

Pasithea Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Capital Lease Obligation

0.16

0.08

Pasithea Therapeutics Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial														0.03	-	-	-	-

Pasithea Therapeutics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Pasithea Therapeutics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Pasithea Therapeutics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Pasithea Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pasithea Therapeutics Corp (NAS:KTTA) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

1111 Lincoln Road, Suite 500, Miami Beach, FL, USA, 33139

Website

https://www.pasithea.com

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).

Executives

Tiago Marques	director, officer: Chief Executive Officer	1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH FL 33139
Graeme Martin Currie	officer: Chief Development Officer	51 BARBAREE WAY, TIBURON CA 94920
Lawrence Steinman	director	10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Bradford Manning	10 percent owner	C/O PBM CAPITAL GROUP, LLC, 200 GARRETT STREET, SUITE S, CHARLOTTESVILLE VA 22902
Paul B Manning	10 percent owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Tiger Lily Capital, Llc	10 percent owner	C/O PBM CAPITAL GROUP, LLC, 200 GARRETT STREET, SUITE S, CHARLOTTESVILLE VA 22902
Pd Joint Holdings, Llc Series 2016-a	10 percent owner	C/O TIGER LILY CAPITAL LLC, 200 GARRETT STREET, SUITE O, CHARLOTTESVILLE VA 22902
Elderhill Corp	other: Member of 10% owner group	C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T IN5
Concord Ip2 Ltd.	other: Member of 10% owner group	C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T 1N5
David Delaney	other: Member of 10% owner group	C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T 1N5
Eric Shahinian	other: Member of 10% owner group	350 PARK AVE, 13TH FL, NEW YORK NY 10022
Alfred J Novak	director	325 NE 6TH ST, BOCA RATON FL 33432
Camac Partners, Llc	other: Member of 10% owner group	350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022
Camac Capital, Llc	other: Member of 10% owner group	350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022
Camac Fund, Lp	other: Member of 10% owner group	CAMAC CAPITAL, LLC, 350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022